The Medical Letter on Drugs and Therapeutics
Deferiprone (Ferriprox) for Iron Overload
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Revised 2/27/12: The second sentence in the conclusion has been changed to fix a grammatical error.

The FDA has approved deferiprone (de fer’ i prone; Ferriprox – ApoPharma), an oral chelating agent available in Europe since 1999, for use as a second-line treatment of iron overload due to blood transfusions (transfusional hemosiderosis) in patients with thalassemia. Two other iron chelating agents, deferoxamine (Desferal, and others), which is usually administered subcutaneously, and oral deferasirox (Exjade), are available for use as first-line therapy in the US.

IRON OVERLOAD — Iron overload is a complication of long-term transfusion therapy in patients with diseases such as beta-thalassemia, sickle cell anemia and myelodysplastic syndrome. It can damage the liver, pancreas, other endocrine organs and the heart.1 Cardiac damage can lead to arrhythmias, congestive heart failure and death. Deferoxamine can prevent these effects, but ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deferiprone (Ferriprox) for Iron Overload
Article code: 1384c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian